Washington, DC – Friends of Cancer Research (Friends) is excited to announce the addition of Dr. Janet Woodcock, Former Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) and Paul Kim, Principal of Kendall Square Policy Strategies LLC, to its Board of Directors.
Dr. Janet Woodcock has had a profound impact on patient care and regulatory science through an illustrious career at the FDA. Dr. Woodcock has been a key advocate and ally for Friends for over 25 years, playing a critical role in our efforts to ensure patients have access to the latest treatments and trials.
“I’m honored to be joining the Board of such an impactful organization. Friends has and will continue to do so much for cancer patients, providing new hope through integration of science and policy.” – Dr. Janet Woodcock
Most recently, Dr. Woodcock served as Principal Deputy Commissioner, spearheading a major reorganization of FDA’s foods program and the Office of Regulatory Affairs. Prior to that Dr. Woodcock served as Acting FDA Commissioner.
Dr. Woodcock served as Director of CDER for over 20 years in addition to holding other senior positions at the FDA including at the Center for Biologics Evaluation and Research. During the COVID pandemic she was the therapeutics lead for “Operation Warp Speed.”
Mr. Paul Kim brings a wealth of knowledge in federal life sciences and public health policy, in particular FDA and public health issues. With over 30 years of experience in public policy, Mr. Kim has been integral in informing and shaping public health in the United States.
“It is an honor and privilege to serve Friends, which for decades has been an essential voice in Washington for patients living with cancer. I hope to help them continue to achieve important innovations in both research and policy.” – Mr. Paul Kim
Mr. Kim currently serves as principal of Kendall Square Policy Strategies LLC, providing advice on the FDA, life science, and public health policy. Previously, Mr. Kim was head of the FDA and federal government strategies practices at a leading law firm for 20 years, representing leading biotechnology, pharmaceutical and medical technology companies, trade associations, and patient advocacy groups before the FDA, the Centers for Medicare and Medicaid Services (CMS), HHS ASPR/BARDA, and Congress.
Earlier in his career, Mr. Kim served as counsel to the late Senator Edward Kennedy, Congressman Henry Waxman, and Senator David Pryor.
“We are honored to welcome Dr. Janet Woodcock and Paul Kim to the Friends of Cancer Research Board of Directors,” said Friends’ Chair & Founder, Dr. Ellen Sigal. “Both bring an extraordinary depth of expertise, vision, and unwavering dedication to improving patient outcomes. Janet’s transformative leadership at the FDA and Paul’s exceptional contributions to public health policy will undoubtedly strengthen our mission to drive progress in cancer research and treatment. We look forward to having them join us in this vital work.”
To learn more about Friends Board of Directors click here.
